| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 06/26/2008 | US20080155717 Polycomb genes from maize - mez1 and mez2 |
| 06/26/2008 | US20080155716 Serine hydroxymethyltransferase as target for herbicides |
| 06/26/2008 | US20080155715 Stress-Responsive Root-Specific Genes |
| 06/26/2008 | US20080155714 oil producing crop plant is produced by transfecting; efficient production of cyclopropane fatty acids in an oilseed crop; forming biodegradable lubricants from plant oil; intermediates to branched fatty acids with the low temperature properties and resist to oxidation |
| 06/26/2008 | US20080155712 Means for identifying nucleotide sequences involved in apomixis |
| 06/26/2008 | US20080155711 Cotton variety st 5327b2rf |
| 06/26/2008 | US20080155710 Cotton variety st 4427b2rf |
| 06/26/2008 | US20080155708 novel cotton variety designated STX0502RF. Provided by the invention are the seeds, plants, plant parts and derivatives of the cotton variety STX0502RF. Also provided by the invention are tissue cultures of the cotton variety STX0502RF and the plants regenerated therefrom. |
| 06/26/2008 | US20080155707 novel cotton variety designated STX0502RF. Provided by the invention are the seeds, plants, plant parts and derivatives of the cotton variety STX0502RF. Also provided by the invention are tissue cultures of the cotton variety STX0502RF and the plants regenerated therefrom. |
| 06/26/2008 | US20080155706 Nucleic acid sequence for forming a transgenic plant with at least one of: tolerance to salt, sucrose, cold weather, drought, low nitrogen conditions, and that flowers earlier and for longer; legumes |
| 06/26/2008 | US20080155705 Method For the Production of Multiple-Unsaturated Fatty Acids in Transgenic Organisms |
| 06/26/2008 | US20080155703 Identifying new immunomodulatory chemical entities (NICE); reacting a candidate NICE with a Tat SH3 binding domain, identifying the bound candidate NICE and determining whether it induces monocytes to differentiate into dendritic cells (DC) or regulatory macrophages (AReg); drug screening; immunotherapy |
| 06/26/2008 | US20080154028 Novel calcium-independent phospholipases A2, genes thereof and promoter of the same |
| 06/26/2008 | US20080154027 nucleotide sequences comprising a Yarrowia genetic translation initiation site, for encoding desaturases |
| 06/26/2008 | US20080153772 Oligonucleotides For Rna Interference and Biological Applications Thereof |
| 06/26/2008 | US20080153771 Selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological neovascularization (NV) tissues; cancer, ocular disease, arthritis, and inflammatory diseases |
| 06/26/2008 | US20080153770 Expression Vectors with Improved Safety |
| 06/26/2008 | US20080153769 A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass |
| 06/26/2008 | US20080153768 Treatment of neurological disorders by dsrna administration |
| 06/26/2008 | US20080153767 Modulation of forkhead box o1a expression |
| 06/26/2008 | US20080153766 Non-insulin dependent diabetes mellitus; lowers hepatic fatty degeneration; improving liver function by reducing alanine transaminase and aspartate transaminase levels |
| 06/26/2008 | US20080153765 Inducing apoptosis in a bcl-6-expressing cell or a non-Hodgkin's lymphoma cell; nucleic acid molecule having a sequence corresponding to or complementary to accessible regions of bcl-6 mRNA, vectors, cells, |
| 06/26/2008 | US20080153764 Used in cells and transgenic animals for a variety of applications including producing and studying the effects of RNAi and microRNA mediated gene silencing. |
| 06/26/2008 | US20080153763 Contains only promoter and transcription sequence regions which minimizes immunogenicity because it does not contain extra sequences; resistant to digestion and relatively stable in serum and cells |
| 06/26/2008 | US20080153756 Nucleic acids encoding them; for use in modulating alpha 4 integrin function; kits; antibodies against the peptides |
| 06/26/2008 | US20080153754 Phenotypic reversion of pancreatic carcinoma cells |
| 06/26/2008 | US20080153751 Albumin Fusion Proteins |
| 06/26/2008 | US20080153750 Fermenting an appropriate microorganism using glucose as a carbon source and separating by chromatography, has a purity of at least 98%; specific binding or targeting to transferrin; use in the treatment of CNS neoplasm; antitumor agents |
| 06/26/2008 | US20080153747 taipan natriuretic peptide is used for treating congestive heart failure, stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth; antigen-binding molecule |
| 06/26/2008 | US20080153745 Compositions of tRNA and uses thereof |
| 06/26/2008 | US20080153737 Method of Delivering Rna Interference and Uses Thereof |
| 06/26/2008 | US20080153733 genetic mutant hydrolases for use in detergents, textile desizing, starch liquefaction and ethanol production; automatic dishwashing detergent, laundry washing; stability, resist to heat and oxidation |
| 06/26/2008 | US20080153712 Universal Libraries for Immunoglobulins |
| 06/26/2008 | US20080153166 Stable lipid-comprising drug delivery complexes and methods for their production |
| 06/26/2008 | US20080153162 Provide anti-viral and other medically useful effects, such as anti-cancer effects; reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in vitro |
| 06/26/2008 | US20080153159 Therapeutic and diagnostic agents |
| 06/26/2008 | US20080153156 Use of specific Factor IX polynucleotide coding sequence designed for optimal expression and use of transcriptional regulatory regions minimized in size so they can be used to express Factor IX, and other genes, in size-constrained environment such as in self complementary gene therapy vector; hemophilia |
| 06/26/2008 | US20080153147 Compositions, organisms and methodologies employing a novel human kinase |
| 06/26/2008 | US20080153133 Metabolically Engineered Escherichia Coli For Enhanced Production of Sialic Acid |
| 06/26/2008 | US20080153132 recombinant ecarin protein that specifically activates prothrombin, being efficiently prepared by the genetic engineering technique; ecarin capable of serving conversion from prethrombin-2 to alpha -thrombin or from prothrombin to meizothrombin via cleavage at the Arg-Ile site |
| 06/26/2008 | US20080153131 Free of transmembrane domain; immunoglobulins; autoimmune diseases |
| 06/26/2008 | US20080153130 Ubp1 Protease Mutant and Its Coding Sequence, Their Applications and Heterogonous Protein Expression System |
| 06/26/2008 | US20080153126 Mutant Aox1 Promoters |
| 06/26/2008 | US20080153107 Isolated PGE synthase, provided from encoding nucleic acid. Methods of production and use. Assays for modulators, especially inhibitors, of PGE synthase activity. |
| 06/26/2008 | US20080153104 Gene Overexpressed in Cancer |
| 06/26/2008 | US20080153102 Rooted plant assay system |
| 06/26/2008 | US20080153095 Triphosphates having gamma-phosphate with a detectable group attached; detection using charge coupled device camera or photodiode |
| 06/26/2008 | US20080153083 Settings for recombinant adenoviral-based vaccines |
| 06/26/2008 | US20080152700 Two nucleotides containing 5-methylcytosine, the first hybridizing to the promoter region of a c-Ha-ras gene and the second hybridizing to an oncogene; anticarcinogenic agents for melanomas, pancreatic, colon, breast, bladder, lung, leukemia, prostate, lymphoma, and ovarian cancers |
| 06/26/2008 | US20080152689 Devices containing dna encoding neurotrophic agents and related compositions and methods |
| 06/26/2008 | US20080152670 Attenuated; comprising at least two types of foreign genes inserted to allow expression into two different regions in a recombinant feline herpesvirus type 1 genome; one region encodes thymidine kinase; no lethal effect on the proliferation of the virus in the feline herpesvirus 1 genome |
| 06/26/2008 | US20080152667 Neurotoxin/immunoglobulin fusion for use in treatment and prevention of pain and respiratory system disorders |
| 06/26/2008 | US20080152656 Using kallikren specific inhibitor as therapeutic tool in treating cardiocascular disorders; treating soft tissue and bone trauma; tissue repair |
| 06/26/2008 | US20080152654 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 06/26/2008 | US20080152651 Beta-like glycoprotein hormone polypeptide specific immunoglobulin for treatment of autoimmune, inflammatory, (such as rheumatoid arthritis, psoriasis, multiple sclerosis, toxic shock, bone marrow and organ transplantation disorders |
| 06/26/2008 | US20080152647 Using MG1(mucin) specific immunoglobulins to target therapeutic agents to tumor cells |
| 06/26/2008 | US20080152645 Genetically Encoded Multifunctional Compositions Bidrectionally Transported Between Peripheral Blood and the CNS |
| 06/26/2008 | US20080152642 Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| 06/26/2008 | US20080152641 Inhibitors of Siderophore Biosynthesis in Fungi |
| 06/26/2008 | US20080152633 Flavivirus Replicon Constructs for Tumor Therapy |
| 06/26/2008 | US20080152632 Promoter-reporter cells for determining drug metabolism, drug interactions, and the effects of allotype variation |
| 06/26/2008 | US20080152631 Cancer Antigen Peptides Derived from Wt1 |
| 06/26/2008 | US20080152629 Progenitor cell culture for use in partial and/or full restoration of hematopoietic function in patients who have undergone ablative therapy |
| 06/26/2008 | US20080152620 Hemopoietic cytokine for use in diagnosis, prevention and treatment of skin and respiratory disorders |
| 06/26/2008 | US20080152591 Administering the agent to an externally fertilized teleost;detecting a response of the teleost; and comparing the response of the agent-treated teleost with a response in the brain or CNS of an untreated or control teleost |
| 06/26/2008 | US20080152587 TARGETED BINDING AGENTS DIRECTED TO uPAR AND USES THEREOF |
| 06/26/2008 | DE10300335B4 Oxidoreduktase Oxidoreductase |
| 06/26/2008 | DE102006061015A1 Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC A method for purifying RNA on a preparative scale by means of HPLC |
| 06/26/2008 | DE102006061002A1 Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien Method and means for the enrichment, removal and detection of gram-positive bacteria |
| 06/26/2008 | DE102006060799A1 RSV F-Protein und seine Verwendung RSV F protein and its use |
| 06/26/2008 | DE102006060381A1 Pichia stiptis L-arabinose transporter polypeptide useful for producing bioethanol |
| 06/26/2008 | CA2698307A1 Histophilus somni antigens, compositions and methods of use |
| 06/26/2008 | CA2675245A1 Use of lecithin:retinol acyl transferase gene promoter methylation in evaluating the cancer state of a subject |
| 06/26/2008 | CA2673331A1 Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| 06/26/2008 | CA2673222A1 Variants of vegfr and their use in the diagnosis and treatment of pregnancy associated medical conditions |
| 06/26/2008 | CA2673215A1 Enhanced expression from the pm promoter |
| 06/26/2008 | CA2672937A1 Inhibitory polynucleotide compositions and methods for treating cancer |
| 06/26/2008 | CA2672784A1 Anti-tumour immunity induction by a non-replicatmg adenovirus encoding tap-1 |
| 06/26/2008 | CA2672773A1 Nucleic acid molecules encoding plant proteins in the c3hc4 family and methods for the alteration of plant cellulose and lignin content |
| 06/26/2008 | CA2672771A1 Nucleic acid constructs and methods for altering plant fiber length and/or plant height |
| 06/26/2008 | CA2672758A1 Activin-actrii antagonists and uses for increasing red blood cell levels |
| 06/26/2008 | CA2672756A1 Polynucleotides and polypeptides involved in plant fiber development and methods of using same |
| 06/26/2008 | CA2672606A1 Compositions and methods to treat muscular & cardiovascular disorders |
| 06/26/2008 | CA2672603A1 Novel laccases, compositions and methods of use |
| 06/26/2008 | CA2672509A1 Tissue-specific and temporal control of transgene expression in a model -animal |
| 06/26/2008 | CA2672488A1 Generation of plants with altered oil, protein, or fiber content |
| 06/26/2008 | CA2671674A1 Genes encoding a novel type of lysophophatidylcholine acyltransferases and their use to increase triacylglycerol production and/or modify fatty acid composition |
| 06/26/2008 | CA2671538A1 Engineered anti-tslp antibody |
| 06/26/2008 | CA2671401A1 Plants having enhanced yield-related traits and a method for making the same |
| 06/26/2008 | CA2670992A1 Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
| 06/26/2008 | CA2669921A1 Human monoclonal antibodies to btla and methods of use |
| 06/26/2008 | CA2669746A1 Optimized non-canonical zinc finger proteins |
| 06/26/2008 | CA2662506A1 Glms riboswitches, structure-based compound design with glms riboswitches, and methods and compositions for use of and with glms riboswitches |
| 06/25/2008 | EP1935991A2 Nucleic acid vaccines for prevention of flavivirus infection |
| 06/25/2008 | EP1935989A1 Method for determination of the length of g-tail sequence and kit for the method |
| 06/25/2008 | EP1935988A1 Method of constructing gene expression image and system for constructing gene expression image |
| 06/25/2008 | EP1935981A1 Process for producing recombinant protein |
| 06/25/2008 | EP1935980A1 Mutant luciferase |
| 06/25/2008 | EP1935979A2 Antigenic meningococcal peptides |
| 06/25/2008 | EP1935978A1 Method of controlling decomposition of protein by tetracycline antibiotic |